Hopp til hovedinnhold

Rituksimab ved MS

Sist revidert:
Sist revidert av:
  1. Hauser SL, Bar-Or A, Comi G et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017 Jan19;376(3):221-234. pmid:28002679 PubMed  
  2. Montalban X, Hauser SL, Kappos L et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-220. pmid:28002688 PubMed  
  3. Holmøy T, Fogdell-Hahn A, Svenningsson A. Serum sickness following rituksimab therapy in MS. Neurol Clin Practic 2019:9; 61-3 (epup ahead of print)
  4. Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Rituximab for the treatment of multiple sclerosis: a review. J Neurol. 2022 Jan;269(1):159-183. PMID: 33416999 PubMed  
  5. Hellgren J, Risedal A, Källén K. Rituximab in multiple sclerosis at general hospital level. Rituximab in multiple sclerosis at general hospital level. Acta Neurol Scand 2020.
  6. Luna G1, Alping P1,2, Burman J3, Fink K2, Fogdell-Hahn A2, Gunnarsson M4, Hillert J2, Langer-Gould A5, Lycke J6, Nilsson P7, Salzer J8, Svenningsson A9, Vrethem M10, Olsson T2, Piehl F2,11,12, Frisell T1. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2019. pmid:31589278 PubMed  
  7. Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol 2020. pmid:32056253 PubMed  
  8. Sammaritano LR, Bermas BL, Chakravarty EE et al. 2020 American College of Rheumatology Guidelines for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020 Apr;72(4):529-556. PMID: 32090480 PubMed  
  9. Rød BE, Torkildsen Ø, Myhr KM, Bø L, Wergeland S. Safety of breast feeding during rituximab treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2022 Jul 25:jnnp-2022-329545. doi: 10.1136/jnnp-2022-329545. Epub ahead of print. PMID: 35879056 PubMed  
  10. Krysko KM, LaHue SC, Anderson A, Rutatangwa A, Rowles W, Schubert RD, Marcus J, Riley CS, Bevan C, Hale TW, Bove R.. Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions. Neurol Neuroimmunol Neuroinflamm 2019. pmid:31719115 PubMed  
  11. Ciplea AI, Langer-Gould A, de Vries A, Schaap T, Thiel S, Ringelstein M, Gold R, Hellwig K. . Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2020. pmid:32327455 PubMed  
  • Øyvind Thorkildsen, spesialist i nevrologi, professor PhD
  • Trygve Holmøy, spesialist i nevrologi, professor PhD
  • Gro Owren Nygård, spesialist i nevrologi, PhD
  • Åslaug Rudjord Lorentzen, spesialist i nevrologi, PhD
  • Lars Bøe, spesialist i nevrologi, professor PhD
  • Unn Ljøstad, spesialist i nevrologi professor PhD
  • Åse Mygland, spesialist i nevrologi professor dr med